Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies – Business Development, Entrepreneurship, Careers, Investing, Science, Patents and Regulations

Product Description
Building Biotechnology helps readers start and manage biotechnology companies and understand the business of biotechnology. This acclaimed book describes the convergence of scientific, political, regulatory, and commercial factors that define the scope of biotechnology. In addition to its popularity among business professionals and scientists seeking to apply their skills to biotechnology, Building Biotechnology has also been adopted as a course text in more than fifteen advanced biotechnology programs including MBA programs at UC Irvine, Tepper, and Schulich; the Johns Hopkins biotechnology MS/MBA program; and extension programs at Berkeley and UC San Francisco. This second edition significantly expands upon the foundation laid by the first, updating case law and business models in this dynamic industry and adding significantly more case studies, informative figures and tables.

Buy from AMAZON Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies – Business Development, Entrepreneurship, Careers, Investing, Science, Patents and Regulations

Are Pharmaceutical Companies Immune to Recession

Are Pharmaceutical Companies Immune to Recession

The world is going through a crucial time. Recession has hit the world and all industries; more or less, are affected by it. All of a sudden, uncertainty has become a part of almost all the sectors. We have not experienced such a financial crisis since 1930s. The year 2008 was marked by uncertainty and volatility in the global financial environment. The consequences of the financial crisis have caused severe inflationary pressures. Such an environment has generated deteriorating conditions even for the pharmaceutical industry. On the other hand, pharmaceutical companies have never proven to be a vulnerable sector to volatility and are not completely sensitive to economy.

This is an industry which knows that their industry will not be severely hit as illness never understands financial crisis, even in the hour of recession. People need healthcare regardless of the economy. This is the reason that healthcare providers have been one of the top performers, till now. People are running to invest in healthcare sector as it is considered to be the safest in times like this. The pharmaceutical sector has done fairly well in the US stock market and has brought flow of money in the sector. It is not that pharmaceutical industry has escaped the recession; there is certainly a decrease in growth but not ruthless decline. The sector is not as severely hit as the banking and financial sector or the automotive sector.

Global healthcare spending is definitely going to expand as the life expectancy has grown in the past. Long lived consumers will increase the demand for pharmaceuticals. As per the US census bureau, 24% of the nation’s population is 55 years and older as of July 1, 2008. Further, it has forecasted that the number of people in this age group would increase to approximately 97 million by 2020. The growing population in US, combined with chronic disease will ensure continued growth of the pharmaceutical industry.

Pharmaceutical companies are also focusing on merger activities with biotechnology firms. Present economic slowdown has given an opportunity to big pharmaceutical companies; to focus on biotechnology companies, to boost their R&D pipeline. In today’s environment, when the Japanese Yen is rising against US Dollar, Japanese companies are in a better position to buy pharmaceutical or biotech companies.

During the economic downturn pharmaceutical companies are also facing challenges from generic drugs, expiry of patent of some of their blockbuster drugs and hesitance of FDA for new drug approval. In this time of recession, the pharma companies have shown great interest in online marketing. Few companies are taking the help of Search Engine Optimization (SEO) and are witnessing successful results. The company may see strong online brand presence, if online marketing strategy is implemented in the right way. Pharmaceutical companies can also take advantage from various online portals.

In this context, Pharmaceutical Business Review has emerged as a provider of market analysis and business intelligence report on biotechnology, drug discovery, healthcare services, OTC, drug delivery, drug manufacturing, medical devices and CRO (Contract Research Organisation). It keeps the pharmaceutical companies informed on latest news and reports. This helps the companies in analyzing the latest trend of medical and pharmaceutical industries in this time of crisis.

It seems that this tough time is here to stay for all the industries including pharmaceutical sector, but the silver lining is that healthcare spending is going to increase. This will help pharmaceutical companies in growing and the focusing on online marketing which will eventually prove to be highly helpful for the economy.

www.pharmaceutical-business-review.com

 

 

Exploding the Gene Myth: How Genetic Information Is Produced and Manipulated by Scientists, Physicians, Employers, Insurance Companies, Educators , and Law Enforders

Product Description
How Genetic Information Is Produced and Manipulated by Scientists, Physicians, Employers, Insurance Companies, Educators, and Law Enforcers

With a new Preface

“With their rich array of citations and examples . . . [Hubbard and Wald] show how the marriage of science and business . . . has created that most treacherous of American progeny: commerce masquerading as human liberation.”
-Daniel Callahan, The New York Times Book Review

Buy from AMAZON Exploding the Gene Myth: How Genetic Information Is Produced and Manipulated by Scientists, Physicians, Employers, Insurance Companies, Educators , and Law Enforders

Health Insurance Companies See Stocks Soar Post-Mass. Election

The Republican party isn’t the only group celebrating Scott Brown’s surprising Senate win in Massachusetts. Health insurance companies are also reaping the benefit. Brown campaigned and won largely on his opposition to Democratic-led healthcare reform. His presence in the seat belonging to the late Ted Kennedy makes healthcare reform more difficult, if not impossible, to pass. With his victory, the Democrats lost the 60-vote Senate super-majority needed to prevent Republicans from mounting a filibuster and preventing the bill from passing.

As the special election results rolled, many health care investors were optimistic. Brown had been leading in polls for the past several days prior to the election. Their optimism led to the Dow Jones Industrial Average reaching a 15-month high. The stocks of individual health insurance providers were largely responsible for the jump to 10,725.43. Even if political maneuvers in Washington manage to get health insurance reform passed, it will likely be in a further watered-down form.

Congress has spent most of this month negotiating provisions of the nearly $1 trillion-worth bill. Many in the House of Representatives have tried to insert more progressive provisions into the legislation, an effort that will most likely be futile after these Massachusetts election results. The health insurance industry has gradually become more comfortable with the Senate’s less comprehensive version of reform, especially when compared with the bullet they dodged in the form of the public option. Shareholders have followed suit. This development will be even more amenable for them. The probability of healthcare reform legislation failing entirely has increased from 10% to nearly 30% since Brown’s election, according to experts.

Why do health insurance companies and their investors look negatively upon healthcare reform? Obviously, a government-run public option that would be able to compete with and undercut private insurers was a huge threat; however, that possibility appeared like a lost cause even prior to the special election. The Senate plan currently hanging in the balance would provide financial subsidies to uninsured Americans whose annual incomes fall under specified income levels. That would bring millions of new customers to the market seeking low cost medical insurance. The trade-off for insurers is that they would have to participate in regulated federal exchange markets in order for their plans to be subsidized. These markets come with increased regulations, which will ban health insurance companies from denying coverage to people with pre-existing conditions, charging women more for health insurance than men, or charging older individuals significantly more than younger individuals. All of these new rules have the potential to increase costs and decrease profits for insurers. The chance of not having to contend with those laws is heartening to shareholders.

In total, the investor rally resulted in managed care health insurance stocks trading up by one to five percent. HMOs such as Coventry Health Care (6% increase), Humana (7.1%), and Aetna (4.2%) led the charge. Financial analysts predict that those firms with the largest Medicare Advantage market share will benefit most; the Senate’s healthcare reform proposal includes a cutback of subsidies for that program.

Pharmaceuticals’ stocks also benefited from Massachusetts’ election of Scott Brown. It makes it less likely that drug companies–including Merck, Eli Lilly, and Pfizer–will face shorter patent protection periods for new biotech medications. Unfortunately, hospitals have not been as lucky. Major hospital groups are poised to benefit from healthcare reform, because they shoulder the the cost of treating uninsured patients in their emergency rooms. They would be reimbursed for the cost of treatment if millions of those people acquired medical insurance. With that becoming less likely, the stocks of companies like Tenet are down up to three percent.

Pharmaceutical & Biotech Companies Partner Singapore to Accelerate Innovation in Asia

Pharmaceutical & Biotech Companies Partner Singapore to Accelerate Innovation in Asia
Singapore’s integrated research network that offers multidisciplinary capabilities across basic and translational research has drawn pharmaceutical and biotech companies that seek to improve R&D decision making and accelerate innovation in Asia.

Read more on PR Newswire via Yahoo! Finance

Next Page »